title: Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.
abstract: BACKGROUND
  Dendritic cells (DCs) are the most potent antigen-presenting cell population for activating tumor-specific T cells. Due to the wide range of methods for generating DCs, there is no common protocol or defined set of criteria to validate the immunogenicity and function of DC vaccines.
  
  
  METHODS
  Monocyte-derived DCs were generated during 4 days of culture with recombinant granulocyte-macrophage colony stimulating factor and interleukin-4, and pulsed with tumor lysate produced by hypochlorous acid oxidation of tumor cells. Different culture parameters for clinical-scale DC preparation were investigated, including: 1) culture media; 2) culture surface; 3) duration of activating DCs with lipopolysaccharide (LPS) and interferon (IFN)-gamma; 4) method of DC harvest; and 5) cryomedia and final DC product formulation.
  
  
  RESULTS
  DCs cultured in CellGenix DC media containing 2% human AB serum expressed higher levels of maturation markers following lysate-loading and maturation compared to culturing with serum-free CellGenix DC media or AIM-V media, or 2% AB serum supplemented AIM-V media. Nunclon™Δ surface, but not Corning(®) tissue-culture treated surface and Corning(®) ultra-low attachment surface, were suitable for generating an optimal DC phenotype. Recombinant trypsin resulted in reduced major histocompatibility complex (MHC) Class I and II expression on mature lysate-loaded DCs, however presentation of MHC Class I peptides by DCs was not impaired and cell viability was higher compared to cell scraping. Preservation of DCs with an infusible cryomedia containing Plasma-Lyte A, dextrose, sodium chloride injection, human serum albumin, and DMSO yielded higher cell viability compared to using human AB serum containing 10% DMSO. Finally, activating DCs for 16 hours with LPS and IFN-γ stimulated robust mixed leukocyte reactions (MLRs), and high IL-12p70 production in vitro that continued for 24 hours after the cryopreserved DCs were thawed and replated in fresh media.
  
  
  CONCLUSIONS
  This study examined criteria including DC phenotype, viability, IL-12p70 production and the ability to stimulate MLR as metrics of whole oxidized tumor lysate-pulsed DC immunogenicity and functionality. Development and optimization of this unique method is now being tested in a clinical trial of autologous oxidized tumor lysate-pulsed DC in clinical-scale in recurrent ovarian, primary peritoneal or fallopian tube cancer (NCT01132014).
authors.affiliation: Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, 19104, USA.
authors.forename: Cheryl L-L
authors.initials: CL
authors.lastname: Chiang
authors.forename: Dawn A
authors.initials: DA
authors.lastname: Maier
authors.forename: Lana E
authors.initials: LE
authors.lastname: Kandalaft
authors.forename: Andrea L
authors.initials: AL
authors.lastname: Brennan
authors.forename: Evripidis
authors.initials: E
authors.lastname: Lanitis
authors.forename: Qunrui
authors.initials: Q
authors.lastname: Ye
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Levine
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Czerniecki
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Powell
authors.forename: George
authors.initials: G
authors.lastname: Coukos
mesh_terms: D018929:Cell Culture Techniques / Q000379:methods*; D002454:Cell Differentiation / Q000187:drug effects; D002457:Cell Extracts / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D015925:Cryopreservation; D003470:Culture Media / Q000494:pharmacology; D003713:Dendritic Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D006997:Hypochlorous Acid / Q000494:pharmacology; D018664:Interleukin-12 / Q000096:biosynthesis / Q000378:metabolism*; D007959:Lymphocyte Culture Test, Mixed; D010084:Oxidation-Reduction / Q000187:drug effects; D010641:Phenotype; D013997:Time Factors; D014357:Trypsin / Q000378:metabolism
chemical_list: D002457:Cell Extracts; D003470:Culture Media; D018664:Interleukin-12; D006997:Hypochlorous Acid; D014357:Trypsin
references.citation: Methods Mol Biol. 2010;595:149-63
references.pmid: 19941110
references.citation: J Immunol Methods. 2002 Oct 15;268(2):131-40
references.pmid: 12215381
references.citation: Mol Biotechnol. 2003 Sep;25(1):95-9
references.pmid: 13679640
references.citation: Blood. 1997 Feb 1;89(3):776-9
references.pmid: 9028307
references.citation: Cancer Immunol Immunother. 2003 Mar;52(3):155-61
references.pmid: 12649744
references.citation: Cancer Immunol Immunother. 2002 Mar;51(1):45-52
references.pmid: 11845259
references.citation: Blood. 2002 Jul 1;100(1):230-7
references.pmid: 12070032
references.citation: Semin Immunol. 2010 Jun;22(3):132-43
references.pmid: 20356763
references.citation: Blood. 2003 Oct 1;102(7):2338-44
references.pmid: 12714511
references.citation: Nat Med. 1998 Mar;4(3):328-32
references.pmid: 9500607
references.citation: J Immunother. 2008 Jan;31(1):89-100
references.pmid: 18157016
references.citation: J Immunol Methods. 1999 Feb 1;223(1):1-15
references.pmid: 10037230
references.citation: J Immunother. 2003 Sep-Oct;26(5):412-9
references.pmid: 12973030
references.citation: Cancer Res. 2007 Feb 15;67(4):1842-52
references.pmid: 17293384
references.citation: Nat Immunol. 2004 Sep;5(9):927-33
references.pmid: 15300249
references.citation: Cancer Immunol Immunother. 2000 Jun;49(3):152-6
references.pmid: 10881694
references.citation: J Immunol Methods. 2008 Sep 15;337(2):97-105
references.pmid: 18657542
references.citation: Cytotherapy. 2002;4(1):65-76
references.pmid: 11953043
references.citation: J Transl Med. 2008 Jan 25;6:6
references.pmid: 18221542
references.citation: J Immunol. 2010 Jan 15;184(2):591-7
references.pmid: 20018619
references.citation: Clin Exp Immunol. 2005 Dec;142(3):555-68
references.pmid: 16297169
references.citation: J Clin Oncol. 2009 Feb 20;27(6):945-52
references.pmid: 19139436
references.citation: Clin Cancer Res. 2004 Nov 1;10(21):7260-9
references.pmid: 15534100
references.citation: J Immunol. 2010 Jan 15;184(2):824-35
references.pmid: 20018624
references.citation: Hum Gene Ther. 2003 Mar 20;14(5):483-94
references.pmid: 12691613
references.citation: J Hematother Stem Cell Res. 2001 Aug;10(4):569-78
references.pmid: 11522239
references.citation: Clin Cancer Res. 2008 Aug 1;14(15):4898-907
references.pmid: 18676764
references.citation: BJU Int. 2004 Aug;94(3):412-8
references.pmid: 15291878
references.citation: J Exp Med. 1995 Jun 1;181(6):2109-17
references.pmid: 7539040
references.citation: J Immunol. 1996 Nov 1;157(9):3850-9
references.pmid: 8892615
references.citation: J Hematother Stem Cell Res. 2001 Aug;10(4):553-67
references.pmid: 11522238
references.citation: Melanoma Res. 2003 Oct;13(5):521-30
references.pmid: 14512794
references.citation: Clin Cancer Res. 2009 Jul 1;15(13):4499-507
references.pmid: 19509133
references.citation: Hum Gene Ther. 2002 Sep 1;13(13):1605-10
references.pmid: 12228015
references.citation: J Immunother. 2011 Jan;34(1):45-57
references.pmid: 21150712
references.citation: J Immunol. 1997 Sep 1;159(5):2366-74
references.pmid: 9278327
references.citation: J Clin Oncol. 2011 Jan 20;29(3):330-6
references.pmid: 21149657
references.citation: J Immunol. 2003 Apr 15;170(8):4069-76
references.pmid: 12682236
references.citation: J Transl Med. 2006 Aug 16;4:36
references.pmid: 16914047
references.citation: Transfusion. 2007 Dec;47(12):2290-6
references.pmid: 17764512
references.citation: J Immunother. 2010 May;33(4):352-63
references.pmid: 20386471
references.citation: Nature. 2003 Feb 20;421(6925):852-6
references.pmid: 12594515
references.citation: Cancer Immunol Immunother. 2006 Nov;55(11):1384-95
references.pmid: 16463039
references.citation: J Immunol Methods. 1996 Sep 27;196(2):121-35
references.pmid: 8841451
references.citation: J Immunol. 1995 Mar 1;154(5):2257-65
references.pmid: 7868898
references.citation: Science. 2003 Apr 11;300(5617):337-9
references.pmid: 12690201
references.citation: J Immunother. 2001 Jan-Feb;24(1):66-78
references.pmid: 11211150
references.citation: J Immunol Methods. 2005 Mar;298(1-2):61-72
references.pmid: 15847797